Roche is pressing its case with the EMA for its Duchenne muscular dystrophy gene therapy Elevidys (delandistrogene moxeparvovec) by initiating a further global Phase 3 trial. The study aims to generate additional placebo-controlled evidence to address EMA reservations tied to outcomes from Roche’s prior Embark Phase 3 program. The company said the new dataset is intended to overcome concerns raised in the EMA’s July 2025 stance after Embark missed its primary endpoint, while maintaining a focus on benefit-risk and long-term follow-up. Roche previously sought conditional approval based on its submission and committed to expanding the evidence base. Regulatory strategy here centers on de-risking uncertainty with a design that can better isolate efficacy signals. If EMA accepts the new trial package, Elevidys could face a faster path than if Roche waited purely on post-authorization data. For biotech leadership, it’s a clear example of how gene-therapy manufacturers are iterating trial strategies after regulatory friction—using additional placebo-controlled data to realign the evidentiary story with regulators’ evaluation criteria.